Professor Karen Bush (USA)
The 2017 awardee was Professor Karen Bush who is currently an Adjunct Professor at Indiana University Bloomington and consultant to various pharmaceutical companies and biotech companies.
Professor Bush graduated from Monmouth College, Monmouth, IL with a BA (chemistry major; math physics minor). And went on to gain a PhD from Indiana University, Bloomington, IN (Biochemistry major; Organic chemistry, physical chemistry and organ performance minors).
Professor Bush has been a drug discovery team leader or team member associated with entry of 9 investigational drugs into phase 1 clinical trials. In particular, she was a project team member when FDA approved the following drugs: Aztreonam (Squibb, 1984); Piperacillin-tazobactam (Lederle, 1993), Levofloxacin (Johnson & Johnson/Ortho McNeil, 1998-2005) and Doripenem (Johnson & Johnson/Ortho McNeil, 2007). She was also the Microbiology team leader when Canada and Switzerland approved Ceftobiprole (2008).
Professor Bush has many notable professional activities including a long-standing role with CLSI (NCCLS) where she has been on the Subcommittee on Antimicrobial Susceptibility Testing as both a voting member and advisor. She chaired the Working Group on Extended Spectrum beta-Lactamases (2001), was Chair and/or Secretary, of the Working Group on [Fluoroquinolone] Breakpoints and a member of Working Group on Enterobacteriaceae.
Professor Bush has published 213 Peer-reviewed publications, 230 Meeting Abstracts, 24 Book chapters and 5 Patents.
During the ICC in Taiwan, Professor Bush gave a keynote lecture on a topic in which she is a world authority, that of β-Lactamases.